Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL).

Number of days alive and discharged from the ICU through day 28 tended to be higher in the ilofotase alfa group 15 [0–22] days compared to 10 [0–22] days in the placebo group, but this difference did not reach statistical significance (nominal p value 0.09) (Table 2 ).

also in 111,027 other papers